Clinical Trial Update: Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updating the efficacy and safety of anlotinib hydrochloride combined with nivolumab for gastric adenocarcinoma and esophageal squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN